Clinical Trial Update: Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Male Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Gonadotropin-releasing hormone analogue (gonadotropin-releasing hormone analogue)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Male Breast Cancer | Phase 3 | Status: COMPLETED